Viatris Inc
33 products tracked · names used in filings: Viatris Inc, Viatris Limited
Upcoming milestones
MR-107A-02: PDUFA target action date (moderate-to-severe acute pain)
Viatris Inc (VTRS); meloxicam; NDA; status: set; "The FDA has assigned a PDUFA goal date of December 27, 2026."; filed 2026-08-06 · source
Recent milestones
MR-141: PDUFA target action date (presbyopia)
Viatris Inc (VTRS); phentolamine ophthalmic solution 0.75%; sNDA; status: set; "The FDA has assigned a PDUFA goal date of October 17, 2026."; filed 2026-02-26 · source
Ruxolitinib Viatris (ruxolitinib hemifumarate) approved in the EU
Marketing authorisation to Viatris Limited; Generic · source
low-dose estrogen weekly patch: PDUFA target action date (contraception)
Viatris Inc (VTRS); norelgestromin and ethinyl estradiol; NDA; status: set; "The NDA was accepted under the FDA's 505(b)(2) regulatory pathway, and the FDA has assigned a PDUFA goal date of July 30, 2026."; filed 2026-02-26 · source
Ruxolitinib Viatris (ruxolitinib hemifumarate): CHMP positive opinion
Viatris Limited; Generic · source
Palbociclib Viatris (palbociclib) approved in the EU
Marketing authorisation to Viatris Limited; Generic · source
Palbociclib Viatris (palbociclib): CHMP positive opinion
Viatris Limited; Generic · source
Teduglutide Viatris (teduglutide) approved in the EU
Marketing authorisation to Viatris Limited; Generic · source
Teduglutide Viatris (teduglutide): CHMP positive opinion
Viatris Limited; Generic · source
Products
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.